Anita Afzali, MD, MPH, FACG

The Ohio State University Wexner Medical Center

Poster(s):

• E0343 - Ozanimod Is an Effective Oral Treatment for Patients With Ulcerative Colitis Regardless of Baseline Endoscopic Disease Distribution: A Post Hoc Analysis of the Phase 3 True North Study
  Tuesday, October 25, 2022

  3:00 PM – 5:00 PM ET

• E0344 - Efficacy Outcomes by Symptom-Based Response Status After Induction: Week-48 Results from the GALAXI 1 Trial of Guselkumab in Crohn’s Disease
  Tuesday, October 25, 2022

  3:00 PM – 5:00 PM ET

• E0345 - Efficacy of Deucravacitinib, an Oral, Selective, TYK2 Inhibitor, in Patients With Moderately to Severely Active Ulcerative Colitis and Prior Exposure to Biologic Therapy: Subanalysis From the Phase 2 LATTICE-UC Study
  Tuesday, October 25, 2022

  3:00 PM – 5:00 PM ET